COLOCYNTHIS HOMACCORD  - gnaphalium and citrullus colocynthis fruit without seed injection 
JENAHEXAL PHARMA GMBH

Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective.

----------

Colocynthis Homaccord

Description:
     •        Injection Solution Ingredient Information: Each 1.1ml ampule contains: Gnaphalium polycephalum 3X,10X,30X,200X 2.2mcl each; Colocynthis 4X,10X,30X,200X 8.8mcl each. Inactive ingredient: Sterile isotonic sodium chloride solution.

Indications and Usage:
     •        Colocynthis-Homaccord® Injection Solution is indicated for neuralgia of various origins and locations, especially sciatic neuralgia, intercostal neuralgia and intervertebral disc disorders.

Dosage and Administration:
     •     Adults and children 7 years and older: in acute disorders, 1 ampule per day, otherwise 1 ampule, 1 to 3 times per week IM/SC/IV/ID. Children ages 2 to 6 receive ½ the adult dosage. (2.1)

Dosage Form and Strength:
     •     Injections: 1.1ml ampule

Warnings and Precautions
    If pain persists or worsens, if new symptoms occur, or if redness or swelling is present, the patient should be carefully re-evaluated because  these could be signs of a serious condition.
     •     Pregnancy Category C. Animal reproduction studies have not been conducted with this drug. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This drug should be given to a pregnant woman only if clearly needed.
     •     To report SUSPECTED ADVERSE REACTIONS, contact Heel Inc. at 1.800.920.9203 or info@heelusa.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

1.     Indications and Usage
     1.1    Colocynthis-Homaccord® Injection Solution is classifed as a homeopathic combination drug.
     1.2    Botanical ingredients: Colocynthis (bitter cucumber) Gnaphalium polycephalum (common everlasting)
     1.3    Colocynthis-Homaccord® Injection Solution is indicated for neuralgia of various origins and locations, especially sciatic neuralgia, intercostal neuralgia and intervertebral disc disorders.

2.     Dosage and Administration
     2.1     The dosage schedules listed below can be used as a general guide for the administration of Colocynthis-Homaccord® Injection Solution. Colocynthis-Homaccord® Injection Solution shows individual differences in clinical response. Therefore, the dosage for each patient should be individualized according to the patient’s response to therapy.
 
Adults and children 7 years and older: in acute disorders, 1 ampule per day, otherwise 1 ampule, 1 to 3 times per week IM/SC/IV/ID. Children ages 2 to 6 receive ½ the adult dosage.    
                            
Discard unused solution.

Colocynthis-Homaccord® Injection Solution may be administered intravenously, intramuscularly, subcutaneously, or intradermally. The required dose of Colocynthis-Homaccord® Injection Solution is first withdrawn from the ampule into the syringe, and the syringe is then shaken briefy. Colocynthis-Homaccord® Injection Solution should be administered using a narrow gauge needle (e.g. 22 to 30 gauge). Note: Parental drug products like Colocynthis-Homaccord® Injection Solution should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Colocynthis-Homaccord® Injection Solution is a clear, colorless solution. Discolored solutions should be discarded.   

3.        Warnings and Precautions    
     3.1    Colocynthis-Homaccord® Injection Solution exhibits no known adverse renal, hepatic, cardiovascular, gastrointestinal or central nervous system effects.
     3.2    No harmful or potentially harmful side effects such as central nervous system depression are known. Colocynthis-Homaccord® Injection Solution is generally well-tolerated, however, if symptoms persist or worsen discontinue use.
     3.3    Teratogenic effects: In general, homeopathic drugs are not known to cause direct or indirect harm to the fetus. Pregnancy Category C. Animal reproduction studies have not been conducted with this drug. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect  reproduction capacity. This drug should be given to a pregnant woman only if clearly needed.
     3.4    Drug Interactions: None known
     3.5    Drug / Laboratory Test Interaction: None known
     3.6    Carcinogenesis, mutagenesis, impairment of fertility: Not applicable

 

4.     Use in Specifc Populations
     4.1    Pediatric Use: Colocynthis-Homaccord® Injection Solution can be safely administered to children as young as 2 years. (see Dosage and Administration)
     4.2    Nursing Mothers: It is not known whether any of the ingredients in Colocynthis-Homaccord® Injection Solution are excreted in human milk. However, because many drugs are excreted in human milk, Colocynthis-Homaccord® Injection Solution should be administered with caution to nursing mothers.
     4.3    Geriatric use: Colocynthis-Homaccord® Injection Solution is safe to use in adults 12 years and older. (see Dosage and Administration)

5.     Clinical  Pharmacology
     5.1     The exact mechanism of action of Colocynthis-Homaccord® Injection Solution is not fully understood.

6.     Drug Abuse and Dependence
     6.1    Not applicable for homeopathic drugs

7.     Overdosage
     7.1    Due to the low concentration of active ingredients in homeopathic preparations such as Colocynthis-Homaccord® Injection Solution, adverse reactions following over dosage are extremely unlikely. However, care must be taken not to exceed the recommended dosage.

8.     How Supplied
     8.1    Colocynthis-Homaccord® Injection Solution 1.1ml ampules: Packs of 10 ampules: NDC 50114-7065-1

9.     Storage Conditions
     9.1    Avoid freezing and excessive heat. Store at room temperature. Protect from light.


ColocynthisHoma_Inj_Box.jpg

ColocynthisHoma_Inj_Box.jpg


ColocynthisHoma_Inj insert_Rx2.jpg

ColocynthisHoma_Inj insert_Rx2.jpg

ColocynthisHoma_Inj insert_Rx.jpg

ColocynthisHoma_Inj insert_Rx.jpg

COLOCYNTHIS HOMACCORD  
gnaphalium and citrullus colocynthis fruit without seed injection
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:68275-320
Route of AdministrationINTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS, INTRADERMAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
GNAPHALIUM (UNII: BGI20Z6M57) (GNAPHALIUM - UNII:BGI20Z6M57) GNAPHALIUM3 [hp_X]  in 1.1 mL
GNAPHALIUM (UNII: BGI20Z6M57) (GNAPHALIUM - UNII:BGI20Z6M57) GNAPHALIUM10 [hp_X]  in 1.1 mL
GNAPHALIUM (UNII: BGI20Z6M57) (GNAPHALIUM - UNII:BGI20Z6M57) GNAPHALIUM30 [hp_X]  in 1.1 mL
GNAPHALIUM (UNII: BGI20Z6M57) (GNAPHALIUM - UNII:BGI20Z6M57) GNAPHALIUM200 [hp_X]  in 1.1 mL
CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED (UNII: 23H32AOH17) (CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED - UNII:23H32AOH17) CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED4 [hp_X]  in 1.1 mL
CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED (UNII: 23H32AOH17) (CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED - UNII:23H32AOH17) CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED10 [hp_X]  in 1.1 mL
CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED (UNII: 23H32AOH17) (CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED - UNII:23H32AOH17) CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED30 [hp_X]  in 1.1 mL
CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED (UNII: 23H32AOH17) (CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED - UNII:23H32AOH17) CITRULLUS COLOCYNTHIS FRUIT WITHOUT SEED200 [hp_X]  in 1.1 mL
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:68275-320-101.1 mL in 1 AMPULE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved homeopathic09/09/2009
Labeler - JENAHEXAL PHARMA GMBH (344282590)
Establishment
NameAddressID/FEIBusiness Operations
JENAHEXAL PHARMA GMBH 344282590manufacture

Revised: 9/2009
Document Id: 2e956093-0266-4a5a-8926-610a8ff7cdfd
Set id: 05f405bb-6933-44a1-ab48-05faf19fbb4d
Version: 1
Effective Time: 20090909
 
JENAHEXAL PHARMA GMBH